About Us
Technology & Pipeline
Governance
Investors
Media
Contact

About Us
Technology & Pipeline
Corporate Governance
Investors
Media
Contact

October 20, 2021

Extraordinary General Meeting 2021

The Extraordinary General Meeting was held on Wednesday, 20 October 2021.

Documents

Protokoll extra bolagsstämma 2021 – Oasmia Pharmaceutical AB
Svenska 20 oktober, 2021
Minutes Extraordinary General Meeting 2021 – Oasmia Pharmaceutical AB
Swedish October 20, 2021
Press release – Bulletin from Extraordinary General Meeting in Oasmia Pharmaceutical AB
English October 20, 2021
Proxy Form – Oasmia Pharamceutical AB
English September 20, 2021
Postal voting form – Oasmia Pharmaceutical AB
English September 20, 2021
Press release – Notice of Extraordinary General Meeting in Oasmia Pharmaceutical AB
English September 20, 2021

Calendar

August 24, 2023
Interim report January-June 2023
November 16, 2023
Interim report January-September 2023
February 22, 2024
Year-end report January-December 2023

Corporate Governance

About Us
Technology & Pipeline
Corporate Governance
Investors
Media
Contact

Vivesto AB is a specialty pharmaceutical company focused on thedevelopment of new therapeutic options for patients suffering from hard-to-treatcancers. It has an emerging pipeline of clinical-stage assets targeting late-stagecancers. Apealea® (paclitaxel micellar) is being made available to ovarian cancerpatients through a partnership with Elevar Therapeutics, Inc. Development programsinclude Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxelmicellar, in development for advanced prostate cancer. Vivesto has proprietary drugdelivery technology designed to improve solubility, efficacy and safety.

The Share

Follow the share

Personal data
Cookies

OAS-MA-P-001-SEP2020

Vivesto AB
Vallongatan 1
SE-752 16 Uppsala

Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@vivesto.com